The research from the University of Florida suggests that glucosamine, commonly taken as a joint supplement, may be associated with accelerated progression of Alzheimer’s disease. Here are the key points:
-
Study Overview: The study examined health records and brain tissue to explore glucosamine’s impact on patients with mild cognitive impairment (MCI). Those using glucosamine were found to have a 25% increased likelihood of developing dementia compared to non-users.
-
Mortality Risk: Among patients already diagnosed with Alzheimer’s-related dementias (ADRD), glucosamine was linked to a 25% greater mortality risk.
-
Biological Mechanism: Researchers identified an overactive protein and sugar-tagging pathway in the Alzheimer’s brain, suggesting that glucosamine’s effects are influenced by the biological environment and may disrupt critical processes.
-
Mouse Model Findings: Studies with genetically modified mice confirmed that glucosamine increased sugar attachment to proteins, worsening social memory deficits. Reducing this sugar attachment improved memory performance in mice.
-
Implications: The study raises questions about glucosamine’s safety for individuals with cognitive disorders and suggests a potential focus on metabolic dysfunction in Alzheimer’s research and treatment.
-
Expert Commentary: Researchers emphasized the need for further clinical trials to determine causation and explore how metabolic pathways may play critical roles in neurodegenerative diseases.
Overall, the findings call for more scrutiny regarding popular supplements like glucosamine, especially for older adults at risk of cognitive decline.
